Renown Health Patients and Visitors

RENOWN NEWSROOM

Latest News Releases

Featured News

Careers

Awards & Accreditations

University of Nevada, Reno

Renown Health Foundation



Media Resources

Renown Public Relations Media Icon
Renown Health's Public Relations Team
news@renown.org

Renown Health's public relations team supports media partners in finding experts on diverse health care topics. In addition, we provide information and answer all questions regarding Renown. We look forward to working with you.

Read MoreMedia Resources
  • Media On Campus

    For patient confidentiality purposes, Renown Health policies require media to be escorted by the public relations staff at all times.

    PR staff will gladly make parking arrangements, notify the appropriate hospital staff and help you find your destination.

     

    Stand Ups/Live Broadcasts

    Media may conduct stand ups and live broadcasts on our campuses. In the interest of patient confidentiality and traffic flow, a staff member will help you find the best location for your story.

    We ask you to respect our obligation to protect our patients' well-being and legal right to privacy.

  • Patient Condition Inquiry

    We follow regulations of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) for all patients, including patients of public interest. HIPAA regulations specify which information may and may not be released without authorization from a patient.

    Patient privacy regulations allow us to only share patient condition information about patients that appear in our directory.

    Media inquiries require correct spelling of the patient's first and last name.

     

    Definitions of "Condition" used by Renown Health

    When describing a patient's condition, we can only release the following patient statuses:

    Good - Vital signs such as pulse, temperature and blood pressure are stable and within normal limits. Patient is conscious, comfortable and there are no complications.

    Fair - Vital signs are stable and within normal limits. Patient is conscious and alert although may be uncomfortable or in pain and may have minor complications.

    Serious - Vital signs may be unstable or outside normal limits. The patient is acutely ill or injured and may have major complications.

    Critical - Vital signs are unstable or outside normal limits. There are major complications.

    Note: "Stable" is not a condition.

Press Releases

Number of results found: 9
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page 1 of 1
Skipped to 9 results found. Page 1 of 1
    • Wednesday, Mar 06, 2024

    Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

    Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

    Read More About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

    • Thursday, Jan 18, 2024

    Reno Home to "Great Psychiatry and Mental Health Program;" Renown and UNR School of Medicine Named to Becker's National List

    Becker’s list of Hospitals and Health Systems with Great Psychiatry and Mental Health Programs for 2023 has been published, recognizing professional healthcare leaders across the country.    Renown Health and the University of Nevada, Reno School of Medicine have been recognized among the top programs in the United States. This acknowledgement reflects a commitment from a dedicated team of experienced local professionals providing comprehensive mental health services and advancing the field of psychiatry.    In their announcement, Becker’s highlighted that, “In 2018, a $6 million donation (by the Stacie Mathewson Foundation), funded the creation of the Stacie Mathewson Behavioral Health & Addiction Institute at Renown Health. The institute was formed to address increased prescription drug-related mortality rates and suicide rates in northern Nevada. The department is now fully integrated with University of Nevada School of Medicine's psychiatry residency, child and adolescent psychiatry fellowship programs, and behavioral sciences and clinical psychiatry medical student training. The curriculum emphasizes the value of psychotherapy, psychopharmacology, and interventional psychiatry methods, along with primary care team integration.”   Becker’s editors noted that, “Innovative public and private partnerships with the state include the SOAR early intervention treatment program for those experiencing their first episode of psychosis. A 24-hour crisis stabilization center will open in 2024 for adults with mental health or substance use issues. The Connect Washoe County mental health collaborative, part of the hospital’s community benefit program, hosts the Youth Mental Health Summit, with a number of interventions resulting in reduced use of street and prescription drugs, lower hospitalization rates due to opioid overdose, and fewer cases of intentional suicide mortality in youth.”    “We are honored to be recognized as one of the top psychiatry and mental health programs in the U.S. This achievement reflects the dedication of our integrated team and our unwavering commitment to enhancing the lives of individuals and families affected by mental health challenges. We will continue to strive for excellence and address the diverse needs of individuals struggling with behavioral health issues, said Takesha Cooper, MD, Department Chair of Psychiatry and Behavioral Sciences. “Our team comprises skilled psychiatrists, psychologists, therapists and support staff who collaborate to provide holistic and integrated care for our patients. As the region’s only not-for-profit health system, together with the support of grateful donors like Stacie Mathewson, we will continue to actively engage in outreach initiatives to raise awareness about mental health, reduce stigma and create a community that fosters healing and support.”  Renown Health also earned Forbes' Best Healthcare Employer in Nevada for combatting burnout and ensuring well-being and safety of caregivers. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. For more information, visit renown.org. About the University of Nevada, Reno School of Medicine The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first public medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Since 1969, UNR Med has trained more than 3,900 students, residents and fellows. UNR Med continues to improve the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.

    Read More About Reno Home to "Great Psychiatry and Mental Health Program;" Renown and UNR School of Medicine Named to Becker's National List

    • Tuesday, Nov 23, 2021

    Renown Health Leads Nation With Focus on Clinician and Employee Wellness

    New mental health benefits and two leaders Top Women in Wellness and HR by Ragan Communications Concern about clinician well-being has been top of mind for years, but the pandemic has exacerbated stress and trauma and presented a unique opportunity to reframe core approaches to fostering a thriving workforce. More than ever, clinicians require compassionate, holistic support to ensure that they feel safe, valued and engaged,” begins the introduction to the 2022 Health Care Talent Scan from the American Hospital Association. In line with this new report, Renown Health President and CEO Tony Slonim, MD, D.Ph., and a newly appointed member of the American Hospital Association Board of Directors, has announced a number of additional benefits to address some of the physical and psychological impacts of chronic clinician workforce stressors and to promote rest-and-recuperation strategies, essential for sustaining high-performing clinical teams. In an enterprise-wide communication, Dr. Slonim wrote to Renown Health employees, “I often say good health is a positive connection of a person’s body, mind and spirit. To honor you this holiday season, we have added to your comprehensive benefits package to help you achieve well-being, realize greater financial security, advance your education, enjoy enhanced life balance, and when needed, face illnesses and setbacks with the greatest possible peace of mind.” In addition to offering a $100 cash holiday gift for all frontline employees (up to manager level), Renown leaders are working to remove the stigma and barriers to using mental health services when needed, and reinforcing that seeking help indicates strength, not weakness. “By listening, recognizing and honoring our team member’s emotional health, we are looking to help each other process these experiences, grow from them and emerge more resilient and available to our patients and families,” said Michelle Sanchez Bickley, MS, SPHR, SHRM-SCP, Chief Human Resources Officer. “This could include taking a day off to refresh and recharge or taking advantage of confidential, mental health counseling visits at no charge. We have updated our policy to include mental and emotional well-being as eligible for use of sick leave.” Sanchez-Bickley is the newest inductee to the HR Hall of Fame this week by Ragan Communications, for leading the charge for health care organizations across the United States in employee health, performance management, Diversity, Equity and Inclusion, training and development, and for implementing innovative employee benefits. She is the only health care HR leader named to the Hall of Fame this year. Also named to the national leadership list is Ann Beck, MBA, Chief Financial Officer, who, Ragan Communications noted, “despite being in the middle of a COVID pandemic and economic and financial down turn, was able to drive performance to secure Renown’s workforce and long-term financing to serve this generation and the next.” In addition, hospital staff will be offered free chair massages, courtesy of a local donor organization, MOBE. “Without a doubt, it’s the little things like this, free chair massages, food trucks at lunch time, a hot cup of coffee near the end of your shift, and a sincere “thank you” from a patient or family, that makes all the difference to us as nurses,” said Jana Elliott, DNP, RN, Associate Chief Nursing Officer Acute Services. Clinicians and employees are also encouraged to take vacation time away, and will continue to earn 10 paid holidays plus vacation time, employee recognition and rewards through the Everyday Amazing employee recognition program, enrollment in a free life insurance plan, and offered paid volunteer time and health insurance, 401k retirement planning, and education and tuition reimbursement. Dr. Slonim ended his communication by saying, “This year, as we readjust, realign and restore our way to a new world, I have never been prouder to ‘Be Renown.’ Thank you for standing by us, offering your time and expertise, and helping us emerge stronger people, and a stronger organization through a very challenging time. Please enjoy this holiday season with family and friends, and know you are appreciated.” Renown Health is currently hiring key roles to support the health and well-being of our community. The HR and Recruiting team are providing applicants with support during the application, interview and onboarding processes with a variety of digital and virtual tools. To join the Renown team to help Fight the Good fight, visit https://careers.renown.org.   About Renown Health Renown Health is a locally governed, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. In U.S. News and World Report Best Hospital rankings, Renown Regional Medical Center was listed #1 in the State of Nevada. Renown has a long tradition and commitment to improve the care and the health of our community. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

    Read More About Renown Health Leads Nation With Focus on Clinician and Employee Wellness

    • Wednesday, Nov 25, 2020

    Renown Now Offering rTMS Treatment for Major Depression

    Treatment offers patients safe, non-drug and non-invasive repetitive transcranial magnetic stimulation (rTMS) therapy to treat symptoms of major depression. Renown Health is committed to improving access to vital mental health services in northern Nevada. Today, clinical leaders at the Stacie Mathewson Behavioral Health & Addiction Institute at Renown announced they will offer repetitive transcranial magnetic stimulation (rTMS) therapy for people experiencing Major Depressive Disorder (MDD) under the guidance of a Renown psychiatrist.  According to the National Institute of Mental Health, major depression is one of the most common mental disorders in the U.S. The disease causes people to experience sadness and helplessness, and in some cases, may prevent people from carrying out their daily routines.  “We at Renown are proud of our national reputation as an innovator in implementing new models, technology and systems of care for our community,” said Tony Slonim, MD, DrPH, President and CEO. “We are working to transform care and demonstrate value in a way that appeals to patients and helps clinicians improve outcomes and reduce costs. There is now a sufficient body of evidence to accept the analgesic and antidepressant effect of high-frequency rTMS, and we are pleased to offer this promising therapy.” rTMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. It is typically used when other depression treatments haven't been effective. This treatment for depression involves delivering repetitive magnetic pulses, so it's called repetitive TMS or rTMS. “Depression can be treated; however, for some people, medications and talking with a behavioral health expert may not be enough,” said Renown’s Division Chief of Behavioral Health, Richard A. Charlat, M.D., M.P.H. “We are pleased to offer rTMS therapy for people looking for a new way to fight depression and for whom other treatments may not have given them relief. We are committed to working closely with our patients to find the treatment that works best for them, so they can live their best lives.” “Nevada has the highest prevalence of mental illness and substance use in the nation,” said Steve Shell, vice president of the Stacie Mathewson Behavioral Health & Addiction Institute. “Combine that with the added stress and isolation many are feeling with the COVID-19 pandemic, and we know that offering patients safe, non-drug and non-invasive treatments- as well as essential mental health and addiction services are more important than ever.”   How rTMS Works During an rTMS session, an electromagnetic coil is placed against the person’s scalp near their forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the person’s brain involved in mood control and depression. It's thought to activate regions of the brain that have decreased activity in depression. Though the biology of why rTMS works isn't completely understood, the stimulation appears to impact how the brain is working, which in turn seems to ease depression symptoms and improve mood. There are different ways to perform the procedure, and techniques may change as experts learn more about the most effective ways to perform treatments. On average, patients undergo rTMS treatments for four to six weeks, five days a week for about 40 minutes a day. In all cases, a patient’s doctor will determine a treatment plan that’s best for the patient. This video shows what patients can expect during rTMS therapy.    What Does rTMS Feel Like? rTMS therapy is an easy, in-office experience designed to be positive for patients. During treatment, people are awake, alert, and comfortably reclined in a spa-like chair. The first few treatments may cause discomfort at or near the treatment site, however, this is unlikely to last beyond the first week of treatment.1, 2  “The effects of depression can be devastating for the people battling it, as well as for those who love them,” said Stacie Mathewson. “No matter how dark life may seem, always know, there are incredible behavioral health experts at Renown ready to support and empower you as you seek the help you deserve.”  Charles N. and Stacie L. Mathewson established the Stacie Mathewson Behavioral Health & Addiction Institute at Renown in 2018 to expand community access to prevention and intervention services for mental health disorders and alcohol and drug addiction. Renown is working to expand intensive outpatient treatment, partial hospitalization and medication-assisted treatment programs to better serve those struggling with mental illness and addiction. The Renown team is also passionate about prevention, mental wellness and is actively working to decrease stigma and encourage more people to seek the help they need. TMS therapy is cleared by the FDA and available by prescription only. It is commonly covered by most insurance plans. Patients must be referred by a behavioral expert to seek rTMS treatment. For more information and to make a patient referral, please call the Stacie Mathewson Behavioral Health & Addiction Institute at 775-982-5318.   About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®.   Sources Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40 Rush AJ, et. al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 163(11):1905-1917.

    Read More About Renown Now Offering rTMS Treatment for Major Depression

    • Wednesday, Sep 02, 2020

    Steve Shell Joins Renown to Lead the Stacie Mathewson Behavioral Health & Addiction Institute

    Under Steve Shell's leadership, the Institute will continue to expand community access to prevention and intervention services for mental health disorders and alcohol and drug addiction. Renown Health is excited to announce Steve Shell is joining the Stacie Mathewson Behavioral Health & Addiction Institute at Renown as its vice president. In this role, Shell will oversee the Institute, which provides intensive outpatient treatment, partial hospitalization programs and medication-assisted treatment to serve those struggling with mental illness and addiction in our community. “We are pleased to welcome such an experienced and talented leader like Steve to our organization,” said Tony Slonim, MD, DrPH, president and CEO, Renown Health. “As vice president of the Stacie Mathewson Behavioral Health & Addiction Institute at Renown, Steve will continue the Institute’s work to change the status of mental health and addiction in northern Nevada.” Shell comes to Renown after opening and serving as chief executive officer of Nevada’s two newest behavioral health hospitals since 2013. He was instrumental in establishing Reno Behavioral Healthcare Hospital in 2016 and helped to design, set up and manage operations for the 124-bed psychiatric and addiction treatment facility for all ages. He also launched the 152- bed Desert Parkway Behavioral Healthcare Hospital in Las Vegas in 2013, a psychiatric and addiction treatment facility for all ages. “Nevada has the highest prevalence of mental illness and substance use in the nation combined with limited access to treatment and a shortage of care providers,” said Steve Shell. “I am passionate about improving the health of our community and have dedicated my career to advocating for mental health, working diligently to further elevate the care offered in our state.”  Renown Health and Charles N. and Stacie L. Mathewson established the Stacie Mathewson Behavioral Health & Addiction Institute at Renown in to expand community access to prevention and intervention services for mental health disorders and alcohol and drug addiction.  The Institute is working to expand intensive outpatient treatment, partial hospitalization programs and medication-assisted treatment to better serve those struggling with mental illness and addiction and is working to decrease stigma and encourage more people to seek help. “Moving the needle and improving the heartbreaking statistics of our state is a key focus for the Institute,” said Stacie Mathewson, executive director at the Stacie Mathewson Foundation. “I believe Steve’s leadership will have a positive impact on our efforts to improve the care and treatment of mental illness and addiction.”      About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®.

    Read More About Steve Shell Joins Renown to Lead the Stacie Mathewson Behavioral Health & Addiction Institute

    • Monday, Jul 27, 2020

    Population Genetic Screening Show to Efficiently Identify Increased Risk for Inherited Disease

    Healthy Nevada Project’s community-based approach reveals up to 90% of CDC Tier 1 genetic condition risks missed using clinical care guidelines. In a new study published today in the journal Nature Medicine, researchers behind the Healthy Nevada Project® suggest that community-based genetic screening has the potential to efficiently identify individuals who may be at increased risk for three common inherited genetic conditions known to cause several forms of cancer and increased risk for heart disease or stroke. In 2018, the Healthy Nevada Project® (the largest, community-based population health study combining genetic, clinical, environmental and social data) started notifying consenting study participants who have certain genetic variants which predispose them to the Centers for Disease Control and Prevention (CDC) Tier 1 genetic conditions. The study focused on identifying carriers of these conditions, which include Hereditary Breast and Ovarian Cancer, Lynch Syndrome, and Familial Hypercholesterolemia, because they are the most common conditions and early detection and treatment could significantly lower morbidity and mortality. Initial results from almost 27,000 study participants showed that 90% of carriers of the CDC Tier 1 genetic conditions were not previously identified in a clinical setting. The authors conclude that population genetic screening would identify at-risk carriers not identified during routine care. “Our first goal was to deliver actionable health data back to the participants of the study and understand whether or not broad population screening of CDC Tier 1 genomic conditions was a practical tool to identify at-risk individuals,” explained Joseph Grzymski, Ph.D., the principal investigator of the Healthy Nevada Project®, a research professor at the Desert Research Institute (DRI), chief scientific officer for Renown Health and lead author of the study. “Now, two years into doing that, it is clear that the clinical guidelines for detecting risk in individuals are too narrow and miss too many at risk individuals.” Within the group of 26,906 Healthy Nevada Project® participants that Grzymski’s research team studied, 358 (1.33%) were carriers for CDC Tier 1 conditions. However, only 25% of those individuals met clinical guidelines for genetic screening. Additionally, more than 20% of the carriers already had a diagnosis of disease relevant to their underlying genetic condition. “We’re at a point now where it’s possible to do clinical-grade genetic screening at population-scale,” added James Lu, M.D. Ph.D., co-founder and chief scientific officer of Helix and senior co-author of the study. “What this study demonstrates is the potential impact of doing so. By making genetic screening available more broadly, we can help the millions of Americans who are unaware that they are living at increased risk for highly actionable, genetic conditions take action.” Most notably, the study found that of the 273 participants who were carriers of the CDC Tier 1 genetic conditions and had clinical record information, only 22 individuals showed any previous suspicion of their underlying genetic conditions. “For the first time, we are providing information at the individual level so study participants can make lifesaving changes to reduce their risk based on their genetics,” said Anthony Slonim, M.D., Dr.PH., FACHE, president and CEO of Renown Health and co-director of the Project® study. “We’re conducting research on the community level to develop leading-edge research on health determinants for entire neighborhoods, states and eventually, the country. Returning these results allows us to understand the prevalence of genetically programmed diseases and illnesses that we have here in Nevada and ensure we are providing the best prevention and care plans. For the individual, the return of results can be life changing.” According to the CDC, early detection and intervention of the Tier 1 genetic conditions could have a meaningful potential for clinical action ability and a positive impact on public health. The Healthy Nevada Project®, which launched in 2016, offers free genetic testing to every Nevadan, aged 18 and older, interested in learning more about their health and genetic profile. With more than 50,000 study participants enrolled in four years, the Healthy Nevada Project® has become the fastest-enrolling genetic study in the world. For more about the Healthy Nevada Project® please visit healthynv.org     Renown Institute for Health Innovation is a collaboration between Renown Health – a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute – a recognized world leader in investigating the effects of natural and human induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at Healthynv.org. Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+Ⓡ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research. In response to the COVID-19 public health crisis, Helix has launched a sensitive and scalable end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country. Learn more at www.helix.com.

    Read More About Population Genetic Screening Show to Efficiently Identify Increased Risk for Inherited Disease

    • Friday, Jul 24, 2020

    Introducing Dana Renown Institute for Health Innovations New Life Sized Holographic Kiosk

    Presented by the Desert Research Institute and Renown Health, DANA will help people learn more about the Healthy Nevada Project® and their own unique, genetic health traits What is the Healthy Nevada Project®? What are the benefits of joining this research study? How can I find out if I carry genes for health risks like heart disease, hereditary breast and ovarian cancer syndrome and Lynch syndrome? What if a holographic avatar, powered by artificial intelligence (AI), could answer all these questions and more? DANA has all the answers, she is a virtual assistant with “DNA” in her name, presented by the Renown Institute for Health Innovation (Renown IHI), a collaboration between Renown Health and the Desert Research Institute (DRI). This life-sized, holographic avatar will greet individuals outside Renown Regional Medical Center’s Sierra Café, and talk to them about the Healthy Nevada Project, the world’s largest community-based genetic population health study. Members of the media are invited to meet DANA this morning from 10 a.m. – noon. Please reply to this email or call (775) 691-7308 to coordinate a meet and greet. “Unfortunately, Nevada ranks among the lowest in the nation for health outcomes—and we are working to change that,” said Anthony Slonim, M.D., D.Ph., president and CEO of Renown Health and president of Renown Institute for Health Innovation. “Through the Healthy Nevada Project® , our goal is to offer genetic testing to every Nevadan interested in learning more about their health and genetic profile. Thanks to this advanced technology, DANA will offer people a personalized explanation of the Project, and help them take the next step to better understand their health, and their health risks, so they can modify their behavior and ultimately, live a healthier, happier life.” With more than 51,000 study participants enrolled to date, the Healthy Nevada Project® is considered the fastest-enrolling genetic study in the country. The Project is also the first of its kind to return clinical results to study volunteers, which means participants can learn their genetic risks tied to heart disease and certain cancers, as well as lifestyle changes that could potentially help reduce their risk and prevent disease. Furthermore, participants can choose to share their information with their medical provider to improve and enhance their medical care. “We are always happy to engage with our study participants and look forward to having them meet and engage with DANA,” said Joseph Grzymski, Ph.D., research professor at DRI, principal investigator of the Healthy Nevada Project® and chief scientific officer for Renown Health. “At a time of physical distancing and limiting human contact where possible, using tools like an avatar and AI are important for communicating, whether it be for genetics, vaccinations or other important health information.” Visitors can interact with DANA through a touch screen (cleaned and sanitized after every encounter) to learn more about the study, enter their contact information and schedule an appointment to join the free genetics study or receive more information about their test results. Kiosk visitors are asked to maintain physical distance guidelines and use the hand sanitizer and Sani Wipes available next to the kiosk.     Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org.

    Read More About Introducing Dana Renown Institute for Health Innovations New Life Sized Holographic Kiosk

    • Friday, May 08, 2020

    Seeking Donors Who Have Recovered from COVID-19 to Donate Plasma

    New study, led by physician researchers from Renown Health and University of Nevada, Reno School of Medicine seeks to understand how the immune system responds to COVID-19 with goal of developing a new treatment. Individuals who have recovered from COVID-19 may now be able to help patients currently fighting the infection by donating their plasma. Those who have recovered from the infection may have COVID-19 antibodies in their blood. These antibodies provided one way for their immune systems to fight the virus when they were sick, so their blood may be used to help others fight off the disease through convalescent plasma. Convalescent plasma is a component of blood from recovered patients that may contain precious COVID-19 antibodies. Antibodies are proteins that might help fight the infection. In this study, we will be collecting plasma from patients who have recovered from COVID-19 and investigating its efficacy in helping treat other patients with COVID-19. Convalescent plasma is being investigated for treatment of COVID-19 because there is no approved treatment for the disease and there is information that suggests it might help some patients recover from COVID-19. Renown Health and the University of Nevada, Reno School of Medicine (UNR Med) are leading a study locally to better understand how the body’s immune system responds to the virus, how it presents in northern Nevada and ultimately, aid in developing a new treatment for COVID-19. “Renown and UNR Med are at the forefront of conducting essential research to increase the health and safety of our community,” said Sara Healy, MD, MPH, principal investigator of the study and a pediatric infectious disease physician at Renown Children’s Hospital and UNR Med. “So little is known about effectively treating COVID-19 and we are venturing into new territory. This important study is instrumental in helping us understand the immune systems of people who were affected by COVID-19, and with their help, getting us one step closer to finding a treatment for the disease that has significantly impacted our nation and our community.” “COVID-19 survivors are in a unique and exciting position to be a part of something much bigger than the virus,” said Mark Riddle, MD, DrPH, FISTM, associate investigator of the study and Associate Dean for Clinical Research at UNR Med. “As a participant of this study, not only are you helping us to better understand the disease and the chronic health affects it has long term, but it’s a way to help those suffering from the disease to fight it and hopefully recover. We encourage participation in this important study and invaluable contributions to advancing medicine and our knowledge of COVID-19.” This community-wide study led by physician researchers from Renown Health and UNR Med is a collaborative effort with Vitalant, county and state health districts, Saint Mary’s Medical Center, Northern Nevada Medical Center, Carson Tahoe Health and the VA Sierra Nevada Health Care System, along with the many care providers in our area.   People aged 18-60 in general good health who have fully recovered from COVID-19 for at least two weeks are encouraged to consider donating convalescent plasma as part of this study. There are 332 people, just in Washoe County (as of 5/1/20) who have recovered from COVID-19 and have immune systems that may now be producing antibodies to protect them from becoming infected again with coronavirus. Donated plasma is needed right now, for this clinical trial to determine definitively if this treatment works. Participating in this research study will also make it easier to donate plasma to the Mayo Clinic convalescent plasma program that Renown is a part of in hopes to find a treatment for COVID-19. There is no cost to participate in this study and participation is voluntary. An individual’s decision to participate will not affect their current or future relations with their health care provider(s), health district, or the community. Those who decide to participate are free to withdraw at any time. Confirmed COVID-19 patients who have recovered from the virus and are interested in participating in the study are invited to contact the project coordinators at the Renown Research Office at (775) 982-3646, or via e-mail at covidplasmascreening@renown.org, 7:30 a.m. – 5 p.m., Monday through Friday.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. For more information, visit renown.org. About the University of Nevada, Reno School of Medicine The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Established in 1969, UNR Med is improving the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.

    Read More About Seeking Donors Who Have Recovered from COVID-19 to Donate Plasma

    • Thursday, Jul 11, 2019

    Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

    Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

    Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

Number of results found: 9
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page 1 of 1
Skipped to 9 results found. Page 1 of 1